Interventional Cardiology
Dual antiplatelet therapy
DAPT duration and strategies post-PCI
Unknown pathwayAlso known as: DAPT, dual antiplatelet, P2Y12 inhibitors
2,352
Clinical questions
45
Evidence-backed
0
Claims analyzed
Interventional Cardiology
DAPT duration and strategies post-PCI
Synthesized from 45 evidence-backed clinical questions linked to this topic — 3 supporting the intervention, 7 against the intervention, 1 still contested.
Does antiplatelet vs placebo improve outcomes in Coronary artery stent (device)?
Low Certainty+ Favors benefitantiplatelet vs placebo · Cardiac Output
66 studies (610,362 patients) provide low-certainty evidence for benefit of antiplatelet for Cardiac Output in Coronary artery stent (device).
Does clopidogrel vs aspirin improve outcomes in Non ST segment elevation acute coronary syndrome?
Low Certainty− Favors harmclopidogrel vs aspirin · Cardiac Output
36 studies (358,704 patients) provide low-certainty evidence against benefit of clopidogrel for Cardiac Output in Non ST segment elevation acute coronary syndrome.
Does dual antiplatelet therapy vs placebo improve outcomes in Embolic and thrombotic events (SMQ)?
Low Certainty+ Favors benefitdual antiplatelet therapy vs placebo · Cardiac Output
25 studies (58,232 patients) provide low-certainty evidence for benefit of dual antiplatelet therapy for Cardiac Output in Embolic and thrombotic events (SMQ).
Does vitamin k antagonist vs antiplatelet improve outcomes in Major bleeding - TIMI classification?
Low Certainty− Favors harmvitamin k antagonist vs antiplatelet · Major Bleeding
5 studies (20,372 patients) provide low-certainty evidence against benefit of vitamin k antagonist for Major Bleeding in Major bleeding - TIMI classification.
Does precise-dapt score vs placebo improve outcomes in Major bleeding - TIMI classification?
Low Certainty− Favors harmprecise-dapt score vs placebo
2 studies (14,809 patients) provide low-certainty evidence against benefit of precise-dapt score for the outcome in Major bleeding - TIMI classification.
Does dual antiplatelet therapy vs placebo improve outcomes in Acute Coronary Syndrome?
Low Certainty− Favors harmdual antiplatelet therapy vs placebo
10 studies (4,104 patients) provide low-certainty evidence against benefit of dual antiplatelet therapy for the outcome in Acute Coronary Syndrome.
No claims extracted for this topic
Specific, answerable questions in this area — each with its own synthesized evidence and consensus. Open one to see the forest plot, source trials, and how the consensus has changed over time.
Does antiplatelet vs placebo improve outcomes in Coronary artery stent (device)?
Low Certainty+ Favors benefitantiplatelet vs placebo · Cardiac Output
Does dual antiplatelet therapy vs placebo improve outcomes in Embolic and thrombotic events (SMQ)?
Low Certainty+ Favors benefitdual antiplatelet therapy vs placebo · Cardiac Output
#bruinhearts VA Journal Club: DAPT MVD
UCLA #bruinhearts Journal Club Section — Fri, Aug 14, 11:00 AM EDT — 2 attended
CCU Journal Club: PLATO Trial
UCLA #bruinhearts Journal Club Section — Tue, Jul 28, 3:00 PM EDT — 5 attended
Sessions from public journal clubs on Synapse. RSVP to join the live discussion.
Evaluation of Systolic Blood Pressure, Use of Aspirin and Clopidogrel, and Stroke Recurrence in the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke Trial
JAMA Network Open — Havenon A — Jun 2021
Empiric treatment with aspirin and ticagrelor is the most cost-effective strategy in patients with minor stroke or transient ischemic attack
International Journal of Stroke — Narasimhalu K — Sep 2023
Reaching cardiovascular prevention guideline targets with a polypill-based approach: a meta-analysis of randomised clinical trials
Heart — Selak V — Jun 2018
Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk
JAMA Cardiology — Lee M — Dec 2023
The Extended Safety and Efficacy of Indobufen in Conjunction With P2Y12 Receptor Inhibitors Among Patients Undergoing Revascularization: A Meta‐Analysis and Overview
Follow this topic to get a weekly “what changed” evidence digest and alerts when journal clubs schedule sessions on it.
Dual antiplatelet therapy (also known as DAPT, dual antiplatelet, P2Y12 inhibitors). DAPT duration and strategies post-PCI
Synapse tracks 6 specific clinical questions in Dual antiplatelet therapy, each synthesized independently from its own trial evidence. They include: "Does antiplatelet vs placebo improve outcomes in Coronary artery stent (device)?"; "Does dual antiplatelet therapy vs placebo improve outcomes in Embolic and thrombotic events (SMQ)?"; "Does clopidogrel vs aspirin improve outcomes in Non ST segment elevation acute coronary syndrome?"; "Does vitamin k antagonist vs antiplatelet improve outcomes in Major bleeding - TIMI classification?"; "Does oral antiplatelet agents vs placebo improve outcomes in Acute Coronary Syndrome?".
As of 2026-08-15, the scientific consensus on Dual antiplatelet therapy is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/dual-antiplatelet-therapy.
Deterministic synthesis from Synapse's enriched corpus — 130 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore every Dual antiplatelet therapy paper on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Dual antiplatelet therapy papersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers
Cardiovascular Therapeutics — Yi M — Jan 2025